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Abstract
Primary open angle glaucoma (POAG) is a leading cause of blindness worldwide. The molecular signaling involved in the
pathogenesis of POAG remains unknown. Here, we report that mice lacking the a1 subunit of the nitric oxide receptor
soluble guanylate cyclase represent a novel and translatable animal model of POAG, characterized by thinning of the retinal
nerve fiber layer and loss of optic nerve axons in the context of an open iridocorneal angle. The optic neuropathy associated
with soluble guanylate cyclase a1–deficiency was accompanied by modestly increased intraocular pressure and retinal
vascular dysfunction. Moreover, data from a candidate gene association study suggests that a variant in the locus
containing the genes encoding for the a1 and b1 subunits of soluble guanylate cyclase is associated with POAG in patients
presenting with initial paracentral vision loss, a disease subtype thought to be associated with vascular dysregulation. These
findings provide new insights into the pathogenesis and genetics of POAG and suggest new therapeutic strategies for
POAG.
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Introduction
Glaucoma is a progressive eye disease that ultimately leads to
blindness due to the irreversible loss of retinal ganglion cells
(RGCs) with concomitant optic nerve degeneration [1]. Over
4 million Americans and 65 million people worldwide have
glaucoma, making it the leading cause of blindness in the US
and the second leading cause of blindness worldwide. Although
available therapies delay disease progression [1], protection
remains incomplete and vision loss due to glaucoma cannot be
regained, highlighting the need for novel therapeutic approaches
and drug targets [2]. In primary open-angle glaucoma (POAG),
one of the most common glaucoma subtypes, there is variable
elevation of intraocular pressure (IOP) associated with impaired
aqueous outflow that occurs despite normal anterior segment
anatomy and an open iridocorneal angle [1].
Although multiple POAG risk factors have been identified [2],
the etiology of POAG remains to be elucidated, likely because the
disease can be stratified into various subtypes defined by discrete
but yet unknown biochemical pathways. Two major pathophys-
iologic mechanisms for POAG have been proposed. In the
‘‘mechanical theory’’ [1,2,3,4] optic neuropathy is caused by
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e60156increased IOP, an important risk factor for glaucoma [5,6]. While
elevated IOP is currently the only risk factor amenable to
treatment, some patients with high IOP do not develop POAG
and other patients with low or normal IOP do, suggesting that
other pathologies may contribute to the etiology of POAG [2,6].
Alternatively, a vascular component has been hypothesized to
contribute to POAG pathophysiology. Intravenous administration
of the endothelial and NO-dependent vasodilator acetylcholine,
fails to mediate brachial artery vasodilation in untreated POAG
[7]. Also, flow-mediated vasodilation [8] and retinal vascular
autoregulation [9] are impaired in POAG. Furthermore, POAG
patients with initial paracentral visual field loss tend to have more
frequent systemic vascular risk factors such as migraines and
hypotension [10], and low ocular perfusion pressure (mean arterial
blood pressure – IOP) is a risk factor for POAG [11,12]. However,
the extent to which vascular dysfunction contributes to glauco-
matous optic neuropathy remains to be elucidated and is
controversial [3,4].
Nitric oxide (NO) is an attractive candidate as a factor that
could modify both mechanical and vascular events in POAG
pathogenesis. NO, an important modulator of smooth muscle
function, is synthesized by a family of three enzymes referred to as
NO synthases (NOSs), all of which are expressed in the eye
[13,14,15]. NO activates the cGMP-generating heterodimeric
enzyme soluble guanylate cyclase (sGC). sGC consists of one a and
one b subunit and mediates many of the physiological effects of
NO, including the ability of NO to relax smooth muscle cells
[16,17]. Two isoforms of each sGC subunit have been identified
(a1, a2, b1, and b2), but only the sGCa1b1 and sGCa2b1
heterodimers appear to function in vivo [18].
NO-cGMP signaling has been suggested to participate in the
regulation of aqueous humor (AqH) outflow and IOP [19,20].
Preclinical studies have demonstrated the ability of NO-donor
compounds to lower IOP [21,22] and enhance tissue oxygenation
of the optic nerve head [23]. Importantly, NO metabolites and
cGMP levels are decreased in plasma and AqH samples from
POAG patients [24,25]. Moreover, two independent studies have
identified NOS3 gene variants that are associated with POAG in
women [26,27]. A third study that did not find an association
between NOS3 variants and POAG had a small sample size and
did not provide gender specific results [28]. Together, these
findings suggest that impaired NO-cGMP signaling can contribute
to the etiology of POAG [29,30]. Several mechanisms, including
genetic variation and oxidative stress can regulate NO-cGMP
signaling. However, the mechanisms by which NO-cGMP
signaling modulates POAG risk and whether impaired NO-cGMP
signaling can result in POAG remain unclear.
Here, we identify mice deficient in sGCa1 (sGCa1
2/2 mice) as
a new murine model of POAG characterized by age-related optic
neuropathy, an age-related increase in IOP, and retinal vascular
dysfunction. Moreover, in a nested case-control study, we
identified a genetic association between the locus containing the
genes encoding the a1 and b1 subunits of sGC and a subtype of
POAG characterized by paracentral vision loss and vascular
dysregulation.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Housing
and all procedures involving experimental animals (mice) de-
scribed in this study were specifically approved by the Institutional
Animal Care and Use Committees (IACUC) of Massachusetts
General Hospital (Subcommittee on Research Animal Care), and
the Schepens Eye Research Institute. All procedures were
performed under adequate anesthesia, and all efforts were made
to minimize suffering. The Institutional Review Board of the
Massachusetts Eye and Ear Infirmary, Harvard School of Public
Health, and Brigham and Women’s Hospital approved the gene
association studies described. All participants provided written
informed consent. The Human Research Committees of Massa-
chusetts Eye and Ear Infirmary, Partners Healthcare System, and
the Harvard School of Public Health approved the consent
procedure.
Animals
Age-matched, one- to 17-month-old female sGCa1
2/2 mice
and WT mice on a 129S6 background were studied [31]. Mice
were anesthetized (for AqH outflow measurements and SD-OCT)
by intraperitoneal (IP) injection of ketamine (100 mg/kg) and
xylazine (9 mg/kg) or (for IOP measurements and SLO experi-
ments) with isoflurane (2%). Mice were euthanized (for tissue
harvest) using pentobarbital (10 mg IP). Observers masked as to
animal genotype performed all data acquisition and analyses
described.
Histology and immunohistochemistry
Human eyes (obtained from the New England Eye Bank
(Newton, MA)) and mouse eyes were fixed in paraformaldehyde,
embedded in paraffin, sectioned and incubated with antibodies
specific for sGCa1, sGCb1, or a-smooth muscle actin (1:100
dilution; Abcam), followed by reaction with AlexaFluor goat anti-
rabbit or anti-mouse IgG (1:1000, Invitrogen), Dylight donkey
anti-rabbit IgG (1:100, Stratech Scientific), or biotinylated
secondary antibodies.
Retinal flatmounts were prepared from paraformaldehyde-fixed
eyes and stained with anti-bIII-tubulin (1:150 dilution; Millipore)
or anti-SMI32 (1:500 dilution; Covance) antibodies. Stained
RGCs were detected with biotin-, rhodamine-labeled secondary
antibodies using confocal microscopy (Leica-TCS-SP5). For RGC
counting, retinal flat mounts were divided into quadrants:
superior, temporal, nasal, and inferior. Using the optic nerve
head (ONH) as the origin, 3 standard regions that were distributed
at a 1-mm interval along the radius (0.09 mm
2) were selected from
each quadrant: two from the peripheral region (2 mm from the
ONH) and one from the intermediate region (1 mm from the
ONH). 12 rectangular regions of each eye were photographed at
406 magnification with a confocal microscope (Leica TSC SPS
confocal microscope).
For Toluidine Blue staining, mouse eyes were fixed in 2.5%
glutaraldehyde and 2% paraformaldehyde, post-fixed in 2%
osmium tetroxide in 1.5% potassium ferrocyanide, dehydrated,
mid-sagittally sectioned, embedded in Epon-Araldite, and stained.
Spectral domain optical coherence tomography
Retinal nerve fiber layer (RNFL) thickness was measured using
a SD-OCT system (Bioptigen, NC). Pupils of anesthetized mice
were dilated with topical application of 1% tropicamide. SD-OCT
was performed using 100 horizontal raster and consecutive B-scan
lines composed of 1200 A-scans. Total retinal thickness and RNFL
thickness were analyzed using InVivoVue Diver 2.0 software
(Bioptigen). Data were post-processed using a custom-made
algorithm allowing additional filtering to only include RNFL
thickness values between 5.4 and 24 microns in thickness. The
5.4–24 micron range was selected based on the average RNFL
thickness 6 3 times the standard deviation described previously
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automated segmentation analysis, RNFL thickness was measured
in 24 points of a 565 grid using the caliper tool provided by the
Bioptigen software (fig. S1B).
Paraphenylenediamine staining
Optic nerve cross-sections were prepared and axons were
counted as previously described [33]. The myelin sheath of all
axons, and the axoplasma of damaged axons were stained with
paraphenylenediamine (PPD) and examined for glaucomatous
damage. Sections of nerve between the orbit and chiasm were
dissected, processed, embedded in resin, sectioned, and stained
with PPD. To count axons, the optic nerve was outlined at 1006
magnification and its cross-sectional area was automatically
calculated (METAMORPH, Version 4.6r9, Universal Imaging,
Downingtown, PA). Axons were counted manually and marked on
images using the technique described previously [33]. The
program tracked the total area counted and the total axon count
for all images. The total counted area was 10% of the total nerve
area. The final count was calculated and expressed as number of
axons per optic nerve.
IOP measurement
IOP measurements were acquired in anesthetized mice using
a rebound tonometer (Tonolab) as described previously [34]. Five
TonoLab readouts were averaged to obtain a single IOP value per
eye.
Ultrasound bio-microscopy (UBM)
UBM images were acquired and analyzed with a Vevo 770
scanner (VisualSonics), as previously described [35].
Assessment of aqueous humor turnover
AqH turnover was measured noninvasively, using a previously
published fluorophotometric technique [36]. Benzalkonium chlo-
ride (10 ml of a 0.02% solution in saline) was applied to the eye of
anesthetized mice to permeabilize the cornea to fluorescein. After
5 minutes, 10 ml of a 0.02% fluoresce in saline solution was
applied to the eye for 5 minutes. Images were captured from
a focal plane intermediate between the iris and cornea using
a microscope (SZX16, Olympus) equipped with an Olympus
DP72 camera, a GFP filter, and acquisition software (cellSens
Standard 1.2, Olympus). Average pixel intensity in the green
channel was determined in an area of interest free of corneal
defects using ImageJ. AqH clearance was determined by the decay
constant calculated from the relative fluorescent intensity mea-
sured at 10-minute intervals for 60 minutes after a single
fluorescein treatment.
Scanning laser ophthalmoscopy
We previously developed a scanning laser ophthalmoscope
(SLO) for confocal imaging of the mouse retina [37]. The SLO
was used to record, at video rate, the width of the retinal arteries,
visualized by intravenous (I.V.) injection of fluorescein sodium
prior to, during, and after injection of 0.8 mg/kg sodium
nitroprusside. To compute the width of the retinal arterioles,
short segments (approximately 10 pixels in length) of the retinal
arterioles were isolated from the recorded and re-aligned movies at
fixed distances (measurements at 150 mm and 250 mm were
averaged to yield one value/arteriole) from the optic nerve head.
The width of each blood vessel segment was determined in
MatLab as the width at which the pixel intensity dropped to 50%
of the maximum (full width at half maximum, FWHM). The
diameter of retinal arterioles (each 50 frame averages) was
measured at baseline and after I.V. injection of 0.8 mg/kg sodium
nitroprusside (in 50 ml of saline), a dose that was selected because it
was associated with a similar drop in systemic blood pressure in
WT and sGCa1
2/2 mice. The relative change in diameter was
calculated for each blood vessel. Injecting 50 ml of vehicle did not
alter blood pressure or retinal arteriole diameter.
In vivo hemodynamics
Mice were anaesthetized by IP injection with ketamine
(100 mg/kg), fentanyl (50 mg/kg), and pancuronium (2 mg/kg);
intubated; and mechanically ventilated (FiO2=1, 10ml/g, 120
breaths per minute). A saline-filled catheter was inserted into the
left carotid artery for infusion of saline (2 ml/h) and for
measurement of mean arterial blood pressure (MAP) before,
during and after I.V. injection of 0.8 mg/kg sodium nitroprusside.
The sodium nitroprusside-induced decrease in MAP is expressed
as % decrease from baseline.
Statistical analysis for animal data
Statistical analyses (other than for the targeted gene association
study, see below) were performed using Microsoft Excel or Stata
8.0. Normality of data was confirmed using the Shapiro-Wilk test.
IOP, SLO, and MAP comparisons were performed using either
student’s t test when comparing 2 groups, 1-way ANOVA with
Bonferroni post-hoc pairwise testing when groups were stratified
by age, or multivariate linear regression to assess the ability of age
to predict IOP. Least-squares regression analysis for exponential
decay (Y=Ae
2kt) was performed when assessing the change in
aqueous fluorescein concentration (Y) over time (t), and exponen-
tial decay constants were compared using linear regression.
Aqueous fluorescein concentrations and SD-OCT thickness were
analyzed using 2-way repeated measures ANOVA, with post-hoc
comparisons using 1-way ANOVA in circumstances of significant
interaction p-values (e.g. for aqueous humor outflow rate
measurements in 57-week-old mice). Data are presented as mean
6 SD in the text and mean 6 SEM in the figures. P,0.05 was
considered significant.
Association between GUCY1A3/GUCY1B3 single
nucleotide polymorphisms (SNPs) and POAG in the
Glaucoma Gene and Environment (GLAUGEN) study
The GWAS methods have been described previously [38].
Briefly, the GLAUGEN (Glaucoma genes and environment,
dbGaP Study Accession #: phs000308.v1.p1) cohort included 976
POAG cases, defined as individuals with reproducible visual field
defects correlating with clinical evidence of ON degeneration, and
1140 controls drawn from two longitudinal studies (the Nurses
Health Study and the Health Professionals Follow-up study) and
one clinic-based cohort from the Massachusetts Eye and Ear
Infirmary. All participants were residents of the continental United
States and were of European ancestry, confirmed by both self-
identification and genetic markers. Genotyping was performed
using the Illumina 660W-Quad-v1 platform at the Broad Institute
and appropriate quality filters were applied to ensure a clean
dataset. 495,132 SNPs passed quality control filters. POAG-SNP
association in two soluble guanylate cyclase genes (GUCY1A3 and
GUCY1B3) was analyzed. As these genes are adjacent, a list of
SNPs within, between, and in a 50 kb window on either side of the
genes was obtained using the UCSC Genome Browser [39]. These
SNPs were entered into the SNAP proxy search to generate a list
of all genotyped and tagging SNPs on the Illumina 660W-Quad
platform, giving a total of 51 SNPs. Logistic regression for each
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was preformed using PLINK v1.07. The regression model
included age, gender, race, study site, DNA source, DNA
extraction method, and three eigenvectors. A sub-analysis was
restricted to patients with paracentral visual field loss only (defined
as having one or more paracentral scotomas and no peripheral
visual field loss) leaving 175 cases and 1140 controls, and
subsequently stratified according to gender (leaving 106 female
cases and 682 female controls). SAS software was used to sort the
results. To control for multiple comparisons (3 subgroups were
analyzed: 1: POAG vs. control; 2: type of visual field loss; 3:
gender), a Bonferroni correction of 3.3610
24 (51 GUCY SNPs
tested in 3 subsets of patients: 0.05/153=3.3610
24) was applied
to define statistical significance.
Results
Expression of sGC in the mouse and human eye
Although expression of sGC has been detected in ocular tissue,
including cultured human trabecular meshwork (TM) cells [20],
human ciliary body and TM [40], drosophila photoreceptors [41],
as well as rabbit [42], rat [43], and turtle [44] retina, detailed
knowledge of spatial expression of the sGCa1b1 isoform in the eye
is still lacking. Therefore, ocular sGCa1 and sGCb1 localization
was determined histologically in tissue sections of enucleated
human and mouse eyes. sGCa1 and sGCb1 are expressed in three
anatomical sites that may be important for glaucoma. sGCa1 and
sGCb1 are abundantly expressed in the ciliary muscle (CM, fig. 1A
and 1D), suggesting that sGC might modulate CM contractility
and AqH outflow. sGC is also present in the smooth muscle cell
layer of retinal blood vessels in the human and mouse eye (fig. 1B
and 1E), implying that sGC regulates blood flow in the retina, just
as it does in the systemic vasculature. Finally, sGCa1 and sGCb1
are expressed in RGCs (fig. 1C and 1F), suggesting that sGC may
directly regulate RGC function and/or viability.
Retinal and optic nerve damage in sGCa1
2/2 mice
To avoid the potentially confounding effects of systemic
hypertension (a risk factor for POAG [1]) observed in male but
not female sGCa1
2/2 mice [31,45], we included only female mice
in our study that do not develop hypertension, even as they age
[31]. Thickness of the retina and of the RNFL was measured using
spectral-domain optical coherence tomography (SD-OCT), a tech-
nique previously shown to provide reproducible non-invasive
measurements of RNFL thickness in mice [46]. Total retinal
thickness was similar in sGCa1
2/2 and age-matched wild-type
(WT) mice, regardless of their age (fig. 2A and fig. S1). However,
the RNFL was thinner in old sGCa1
2/2 mice than in age-
matched WT mice (fig. 2A and fig. S1). RNFL thickness did not
differ in young, age-matched sGCa1
2/2 and WT mice (fig. 2A
and fig. S1), suggesting that abnormal embryonic development
does not contribute to the observed RNFL thinning associated
with sGCa1-deficiency.
To further characterize RNFL thinning in sGCa1
2/2 mice,
retinal whole mounts from WT and sGCa1
2/2 mice were stained
with either an anti-SMI32 antibody that stains nerve fibers or an
anti-bIII tubulin antibody that stains both ganglion cells and nerve
fibers. SMI32 staining revealed a loss of nerve fibers in whole-
mount retinas isolated from old but not young sGCa1
2/2 mice
(fig. 2B). Moreover, a lower number of RGCs were detected in old
sGCa1
2/2 mice than in age-matched WT mice, a finding that was
confirmed by immunohistochemistry in retinal flat-mounts
(fig. 2C).
Because POAG is typically characterized by optic nerve
damage, we investigated the impact of sGCa1-deficiency on total
axon counts in the optic nerve, visualized using paraphenylene-
diamine staining. The number of axons in twelve-month-old
sGCa1
2/2 mice was less than in age-matched WT mice (fig. 2D).
Together, these results indicate that, in mice, impaired NO-cGMP
signaling results in optic neuropathy, an important feature of
POAG.
Age-related intraocular pressure elevation in sGCa1
2/2
mice
Because IOP is considered the most important risk factor for
POAG, IOP was measured non-invasively in young and old WT
and sGCa1
2/2 mice. No difference in IOP was detected between
young sGCa1
2/2 and age-matched WT mice. In contrast, IOP
was higher in old sGCa1
2/2 mice than in age-matched WT mice
(fig. S2A).
To further investigate the age-dependency of increased IOP
associated with sGCa1-deficiency, we performed longitudinal
measurements of IOP in age-matched sGCa1
2/2 and WT mice.
IOP increased in sGCa1
2/2 but not in WT mice as they aged
from 19 to 37 weeks (fig. 3). Similar results were obtained in
separate validation cohorts of WT and sGCa1
2/2 mice (fig. S2B
and C). Together, these results demonstrate that sGCa1-deficiency
is associated with a subtle age-dependent IOP increase in mice.
sGCa1 deficiency does not alter anterior segment
morphology
Central corneal thickness (CCT) is a risk factor for the
conversion from ocular hypertension to POAG, making CCT
measurements an integral component in the management of
patients diagnosed with glaucoma [5]. In addition, CCT
influences the measurement of IOP via rebound tonometry [47].
CCT, measured histologically, did not differ in age-matched
3863-week-old WT and sGCa1
2/2 mice (8767 and 8769 mm,
respectively; n=8 each; P=0.90) with normal and elevated IOP,
respectively (1461 versus 2161 mmHg; P=5.9610
27). There-
fore, sGCa1-deficiency does not affect CCT and abnormal CCT is
not responsible for the elevated IOPs seen in old sGCa1
2/2 mice
(fig. 4A).
To exclude the possibility that anatomical abnormalities
impairing AqH drainage, such as those observed in DBA/2J mice
[48] or in mice deficient in cytochrome P4501B1 (Cyp1b1
2/2
mice) [49], underlie the elevated IOP observed in older sGCa1
2/2
mice, we examined the morphology of the iridocorneal angle in
12-month-old WT and sGCa1
2/2 mice with normal and elevated
IOP, respectively (15.861.2 and 19.161.7 mmHg; n=3 each;
P=0.041). Morphologically, eyes of sGCa1
2/2 mice appeared
normal, with a clear anterior chamber revealing complex iris detail
and small round pupils. Depth of the anterior chamber (DAC) was
assessed using in vivo ultrasound biomicroscopy. DAC did not differ
in 5663-week-old WT and sGCa1
2/2 mice (0.3460.01 and
0.3360.01 mm in n=4 and 6, respectively; P=0.26) with IOPs of
1662 and 1962 mmHg, respectively (P=4.3610
22, fig. 4B). In
addition, ultrasound biomicroscopy revealed no morphological
abnormalities in sGCa1
2/2 mice that could account for the
elevated IOP measurements. Histological analyses revealed no
apparent iridocorneal abnormalities in 12-month-old sGCa1
2/2
mice, including a normal ciliary body, a well-defined trabecular
meshwork, and a patent Schlemm’s canal (fig. 4C and D).
Importantly, SD-OCT analysis of the iridocorneal angle, capable
of distinguishing between an open and a closed angle (as in old
DBA2/J mice), did not reveal any evidence for angle-closure in 12-
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2/2 mice (fig. 4E and movies S1, S2, S3). Taken
together, these data suggest that sGCa1-deficiency does not alter
the morphology of the anterior segment of the eye and that angle
closure does not underlie the elevated IOP observed in old
sGCa1
2/2 mice.
Decreased aqueous humor turnover in sGCa1
2/2 mice
IOP is determined by the balance between AqH production by
the ciliary body and the rate of AqH outflow through the filtration
angle. The AqH outflow rate was assessed using a fluorophoto-
metric technique in age-matched WT and sGCa1
2/2 mice
(fig. 5A). Monitoring decay of fluorescence provides a noninvasive
index of AqH dynamics in the mouse eye [36]. Twelve-week-old
WT and sGCa1
2/2 mice had similar IOPs and no difference in
the rate of AqH outflow (fig. 5B). In contrast, AqH clearance was
less in 57-week-old sGCa1
2/2 mice with elevated IOP than in
age-matched WT mice (fig. 5C). These data indicate that there is
an age-related decrease in AqH outflow in sGCa1
2/2 mice.
Retinal arterial dysfunction in sGCa1
2/2 mice
We previously reported that systemic vascular dysfunction,
a potential etiologic factor for POAG [7,8,9], is manifest in the
aorta [16], femoral arteries [16], carotid arteries [50], and
mesenteric arteries [45] of both male and female sGCa1
2/2
mice. To assess retinal vascular function [9], we measured retinal
arterial diameter using in vivo laser ophthalmoscopy (SLO,
fig. S3A and B). Treatment with an NO-donor compound
decreased blood pressure similarly in female WT and sGCa1
2/2
mice (5962% and 6063%, respectively, n=5 each; P=0.37).
However, retinal arterial diameter decreased more in female WT
than in sGCa1
2/2 mice (fig. 6 and fig. S3C). An altered retinal
hemodynamic response to a decrease in blood pressure indicates
Figure 1. Localization of sGC a1 and b1 subunits in the human and murine eye. Panels A–C depict tissue sections from human eyes. Panels
D–F depict tissue sections from mouse eyes. A: Ciliary muscle (CM), stained for a-smooth muscle actin (red), sGCa1 (green, upper panel), or sGCb1
(green, lower panel). Both sGCa1 and sGCb1 co-localized with a-smooth muscle actin in CM (yellow in merged images). Scale bars: 100 mm. B:A n
arteriole in the iris (IA) and an arteriole in the retina (RA) were stained for a-smooth muscle actin (red), sGCa1 (green, upper panels), or sGCb1 (green,
lower panels). Both sGCa1 and sGCb1 co-localized with a-smooth muscle actin in the smooth muscle cell layer of arterioles in the iris and retina
(yellow in merged images). ONL: outer nuclear layer, INL: inner nuclear layer. Scale bars: 20 mm. C: sGCa1 (left panel) and sGCb1 (right panel)
expression was detected histologically in the outer nuclear layer (ONL), inner nuclear layer (INL), and ganglion cell layer (GCL, white arrow) of the
retina. sGCa1 and sGCb1 are visualized by green fluorescence. Scale bars: 20 mm. D: Adjacent sections of a wild-type (WT) murine eye were stained for
a-smooth muscle actin (green, left panel) or sGCa1 (red, right panel). sGCa1 co-localized with a-smooth muscle actin in ciliary muscle (CM) and in
arterioles in the ciliary body (CA). The iridocorneal angle is indicated. Scale bars: 50 mm. E: Adjacent sections of a WT murine eye were stained for a-
smooth muscle actin (green, left panel) or sGCa1 (red, right panel). sGCa1 co-localized with a-smooth muscle actin in retinal arterioles (RA). Scale
bars: 50 mm. F: sGCa1 (left panel) and sGCb1 (right panel) expression was detected histologically in the outer nuclear layer (ONL), inner nuclear
layer (INL), and ganglion cell layer (GCL, white arrow) of the mouse retina. sGCa1 is visualized by brown peroxidase stain and sGCb1 is visualized by
green fluorescence. Scale bars: 20 mm.
doi:10.1371/journal.pone.0060156.g001
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sGCa1
2/2 mice.
Association between a genetic locus containing the
genes encoding the a1 and b1 subunits of sGC and POAG
To explore the contribution of sGC to human POAG
pathogenesis, we evaluated 51 single nucleotide SNP located
throughout the genomic region that includes GUCY1A3 and
GUCY1B3 for their association with POAG in humans. GUCY1A3
and GUCY1B3 encode the sGCa1 (inactivated in sGCa1
2/2 mice)
and sGCb1 subunits, respectively, that constitute the predominant
sGC isoform in most types of tissues [51]. We performed a gene
association study among POAG cases and controls from the
Glaucoma Genes and Environment (GLAUGEN) study [38].
None of the tested SNPs were associated with POAG overall
(table 1).
We next hypothesized that POAG in sGCa1
2/2 mice (with
systemic and retinal vascular dysfunction) shares a common
etiology with POAG in patients with paracentral visual field loss,
a subtype of POAG previously suggested to be associated with
vascular dysregulation [10]. Therefore, we focused our analysis on
a subpopulation of POAG patients with initial paracentral
scotomas and no peripheral visual field loss. Given the previously
described interactions between NOS3 and female gender [26] in
POAG, we analyzed men and women separately. The SNP
rs11722059, located in the GUCY1A3/GUCY1B3 intergenic re-
gion, was significantly associated with POAG characterized by
paracentral visual field loss in women (P=3.1610
24, OR=1.90,
CI=1.34–2.69; table 1). Replication of the candidate gene
Figure 2. Retinal nerve fiber layer (RNFL) thinning and glaucomatous optic neuropathy in sGCa1
2/2 mice. A: Quantitative analysis,
assessed by SD-OCT (see also fig. S1), of total retinal thickness (left panel) and RNFL thickness, in young (6-week-old, middle panel) and old (70-
week-old, right panel) wild-type (WT, n=19 and 13, respectively) and soluble guanylate cyclase a1-deficient (sGCa1
2/2) mice (n=15 and 14,
respectively; *P=1.2610
22). B: Representative whole-mount retinas from age-matched young (20-week-old) and old (56-week-old) WT and sGCa1
2/2
mice, reacted with antibodies directed against SMI32, staining retinal nerve fibers yellow. Scale bars: 500 mm. C: Representative confocal images,
taken at a similar distance from the optic nerve, of flat-mounted retinas isolated from age-matched 52-week-old WT and sGCa1
2/2 mice that were
reacted with antibodies directed against bIII Tubulin, and quantitative analysis of the number of RGCs/high-powered field (n=8 and 7, respectively;
*P=3.6610
22). A retinal ganglion cell (red) is indicated by an arrow. Scale bars: 20 mm. D: Representative cross sections through the optic nerve of
52-week-old WT and sGCa1
2/2 mice stained with paraphenylenediamine, and quantitative analysis of the calculated number of axons/optic nerve
(ON). The arrow indicates an injured area in the optic nerve, characterized by the absence of well-formed myelinated axons (n=7 and 6, respectively;
*P=4.9610
22). Scale bars: 25 mm.
doi:10.1371/journal.pone.0060156.g002
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candidate gene association study. Nevertheless, tentative identifi-
cation of a risk variant located in the locus encoding sGCa1 and
sGCb1, both expressed in ocular tissue (fig. 1), highlights the
potential relevance of sGC in the pathogenesis of POAG.
Discussion
In this study, we report that sGCa1
2/2 mice develop POAG,
characterized by RNFL thinning, loss of RGC’s, and optic
neuropathy in the setting of an open iridocorneal angle. An age-
dependent decrease in AqH turnover suggests that an increase in
outflow resistance underlies the elevated IOP observed in old
sGCa1
2/2 mice. In addition, our findings suggest that impaired
NO-cGMP signaling results in retinal vascular dysfunction,
a possible contributor to the pathophysiology of POAG. Impor-
tantly, the relevance of sGCa1
2/2 mice as a new animal model for
POAG is highlighted by the tentative identification of a genetic
association between the genetic locus encoding the a1 and b1
subunits of sGC and a POAG subtype thought to be associated
with vascular dysregulation.
The RNFL contains the RGC axons that converge to form the
optic nerve. Glaucoma is characterized by loss of axons and death
Figure 3. Intraocular pressure (IOP) increases with age in sGCa1
2/2 mice. IOP, measured serially at 2 time points (1961 and 3763 weeks) in
eyes from age-matched wild-type (WT, left panel) and soluble guanylate cyclase a1-deficient (sGCa1
2/2) mice (right panel). While IOP remained
stable in WT mice as they aged from 19 to 37 weeks (1462t o1 4 62 mmHg; n=25; P=0.67), IOP increased in sGCa1
2/2 mice (1462t o1 8 63 mmHg;
n=37; *P=1.9610
28).
doi:10.1371/journal.pone.0060156.g003
Figure 4. Morphology of the cornea and anterior segment does not differ in WT and sGCa1
2/2 mice. A: Representative light microscopic
images of the central cornea in wild-type (WT, left) and soluble guanylate cyclase a1-deficient mice (sGCa1
2/2, right). Central corneal thickness (CCT)
was similar in age-matched WT and sGCa1
2/2 mice. Double arrows: CCT. Scale bar: 200 mm. B: Representative ultrasound biomicroscopy images of
the ocular anterior segment, obtained in WT (upper panel) and sGCa1
2/2 mice (lower panel). The cornea, iris, vitreous, and lens are evident. Depth
of the anterior chamber (DAC, double arrow) did not differ in WT and sGCa1
2/2 mice. C and D: Representative light microscopic images of paraffin
sections stained with hematoxylin and eosin (C, scale bar: 100 mm) or Toluidine Blue (D, scale bar: 50 mm) containing the iridocorneal angles of 12-
month-old WT (left panels) and sGCa1
2/2 mice (right panels). Location of the cornea, iris root, ciliary body (CB), anterior chamber (AC), and
posterior chamber (PC) are indicated. E: Representative SD-OCT images of the ocular anterior segment, obtained in a 12-month-old wild-type mouse
(upper panel), a 12-month-old sGCa1
2/2 mouse (middle panel), and a 12-month-old DBA2/J mouse in which the angle is closed (lower panel).
SD-OCT revealed no morphological abnormalities in sGCa1
2/2 mice that would suggest a closed angle as detected in old DBA2/J mice. See also
Movies S1, S2, S3.
doi:10.1371/journal.pone.0060156.g004
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damage, characterized by thinning of the RNFL and loss of RGCs
in old sGCa1
2/2 but not age-matched WT mice was demon-
strated via SD-OCT and histologic examination. In addition, the
number of optic nerve axons was significantly lower in twelve-
month-old sGCa1
2/2 mice than in age-matched WT mice,
indicating optic neuropathy associated with sGCa1-deficiency.
The observation that RNFL thickness did not differ in young WT
and sGCa1
2/2 mice, neither of which had high IOPs, suggests
that lack of sGCa1 does not directly affect ganglion cell viability
during embryonic development or during the first weeks after
birth.
Figure 5. Decreased aqueous humor outflow rate in sGCa1
2/2 mice. A: Shown is a representative series of images captured from 57-week-
old wild-type (WT) and soluble guanylate cyclase a1-deficient (sGCa1
2/2) mice at 10-minute intervals after application of fluorescein. Scale bars:
2 mm. B: In 12-week-old WT and sGCa1
2/2 mice with similar IOPs (1662 and 1661 mmHg in n=9 and 8, respectively; P=0.91) the rate of AqH
outflow did not differ, as shown by similar relative fluorescent intensities at all time points measured (P=0.99) and similar exponential decay
constants (0.0098 min
21 (r
2=0.997) and 0.0096 min
21 (r
2=0.998), respectively; P=0.12). C: IOP was greater in 57-week-old sGCa1
2/2 mice than in
age-matched WT mice (1862 mmHg and 1661, respectively; n=10 each; P=0.043), and AqH clearance was delayed in sGCa1
2/2 mice, as shown by
a lower exponential decay constant (0.0058 min
21 (r
2=0.972) versus 0.0092 min
21 (r
2=0.976), respectively; P=0.0056) and higher fluorescent
intensities at all time points measured. *P=0.033, 0.0006, 0.024, 0.0029, 0.035, 0.025, between WT and sGCa1
2/2 mice at 10, 20, 30, 40, 50, and
60 minutes, respectively.
doi:10.1371/journal.pone.0060156.g005
Figure 6. Retinal vascular dysfunction in sGCa1
2/2 mice. A: Representative trace depicting the diameter in one segment of a retinal arteriole in
a wild-type (WT) mouse before, during (arrow), and after injection of the NO-donor compound sodium nitroprusside. Dashed lines indicate the
diameter before and after sodium nitroprusside injection. B: Quantitative analysis of the change in diameter (double arrow in fig. 6A) induced by
injection of 0.8 mg/kg sodium nitroprusside in WT and sGCa1
2/2 mice. n=5 mice (3–4 arterioles per mouse were assessed, see also fig. S3).
*P=4.1610
23.
doi:10.1371/journal.pone.0060156.g006
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IOP is the best characterized risk factor but may not explain all
POAG risk. It is becoming increasingly clear that compounds that
do not lower IOP dramatically but that have properties that
address the underlying glaucomatous disease process may be
suitable therapeutic agents [52,53]. For example, brimonidine, an
a2-adrenergic receptor agonist postulated to modulate vascular
reactivity in an NO-dependent manner [54], corrected the retinal
vasculopathy in patients with normotensive glaucoma and retinal
vascular dysregulation [55]. A randomized clinical trial revealed
that brimonidine was superior to timolol in stabilizing visual field
deterioration despite producing only a modest IOP-lowering effect
(,1 mmHg) similar to that of timolol [56]. Together, these data
suggest that strategies, other than lowering IOP, such as those
targeting vascular dysfunction, may be efficacious treatments for
glaucoma [57]. It is important to emphasize that, even though in
the majority of glaucoma clinical drug trials reduction of IOP is
the primary efficacy endpoint, the United States Food and Drug
Administration has expressed interest in drugs that prevent
progression of glaucomatous damage without necessarily lowering
IOP [52,53]. Nonetheless, benefit-to-risk ratio will likely continue
to be determined by drug efficacy and health risk assessment from
clinical trials in comparison to the benchmark, IOP lowering drugs
[52].
Our data demonstrates that impaired NO-cGMP signaling
results in elevated IOP. The observation that IOPs are similar in
young WT and sGCa1
2/2 mice but increase with age in sGCa1
2/
2 but not WT mice indicates that elevated IOP seen in sGCa1
2/2
mice depends on age, an important risk factor for POAG [1].
Similarly modest changes in IOP impact POAG risk in humans,
highlighting the potential biological significance of the increase in
IOP in sGCa1
2/2 mice [58]. For example, a 2 mmHg difference
in IOP distinguished between progression and non-progression in
glaucoma patients [58,59,60]. Additional longitudinal studies are
required to further characterize the exact timeframe of the
increase in IOP associated with sGCa1-deficiency. Examination
(by histology, ultrasound, and SD-OCT) of the iridocorneal angle
and anterior chamber of sGCa1
2/2 mice with elevated IOP did
not reveal any evidence of morphological abnormalities of the
peripheral cornea or outflow pathway illustrating that the outflow
pathway was not physically obstructed (a characteristic of closed-
angle glaucoma). The rate of AqH outflow dynamics, assessed via
a previously reported non-invasive method [36] that will require
validation using a more reliable method [61], was similar in young
WT and sGCa1
2/2 mice but impaired in old sGCa1
2/2 mice
with elevated IOPs suggesting that an increase in outflow
resistance (indicative of POAG) may contribute to the IOP
increase in sGCa1
2/2 mice. The mechanism underlying the age-
dependency of the effect of sGC-deficiency on AqH outflow
dynamics remains to be determined.
The abundant expression of sGCa1 and sGCb1 in the CM,
together with the established role of sGC in mediating smooth
muscle cell relaxation [16,17], suggests that sGC can alter outflow
by regulating smooth muscle-like contractility of the longitudinal
fibers of the CM. The contractile state of smooth muscle tissue is
the target of Rho-kinase inhibitors, currently being tested in
clinical trials for glaucoma and ocular hypertension [62]. It is
conceivable that AqH drainage is similarly influenced by impaired
NO-cGMP signaling and enhanced RhoA-signaling: both could
result in augmented contractility of the longitudinal fibers of the
CM, thereby potentially decreasing AqH drainage and increasing
IOP [63]. However, the possibility remains that sGCa1-deficiency
affects AqH production or that changes in Schlemm’s canal cell or
TM cell volume, previously reported to be modulated by NO-
cGMP signaling [64], contribute to the altered AqH dynamics in
sGCa1
2/2 mice.
The hypothesis that retinal vascular dysfunction contributes to
the glaucomatous phenotype in sGCa1
2/2 mice was based on the
observed peripheral vascular dysfunction in sGCa1
2/2 mice and
on the association of a genetic variant in the locus containing the
sGCa1 and sGCb1 genes with glaucomatous paracentral vision
loss in women, a subtype of POAG previously postulated to be
associated with ocular vascular dysregulation [10]. To test whether
retinal vascular function is affected by sGCa1-deficiency, the
retinal vasculature was visualized via SLO and the diameter of
retinal arteries was measured at baseline and after treatment with
the NO donor sodium nitroprusside. We previously demonstrated
that the ability of a low dose of sodium nitroprusside to reduce
blood pressure was attenuated in sGCa1
2/2 mice, reflecting the
systemic vascular dysfunction associated with impaired NO-cGMP
signaling [31]. In contrast, a high dose of sodium nitroprusside
reduced blood pressure similarly in sGCa1
2/2 and WT mice [31],
a mechanism that involves activation of sGCa2b1 [17]. Systemic
administration of sodium nitroprusside at a dose that decreased
blood pressure similarly in WT and sGCa1
2/2 mice, thereby
avoiding the potential confounding impact on retinal vascular
diameter of differences in systemic blood pressure between WT
and sGCa1
2/2 mice, induced vasoconstriction of the retinal
Table 1. Association between GUCY1A3/GUCY1B3 single nucleotide polymorphisms (SNPs) and POAG in the Glaucoma Gene and
Environment (GLAUGEN) study.
Gender VF loss MA Top SNP P value OR 95% CI Chr N cases N controls
all any A rs9992550 0.04271 1.43 (1.01, 2.02) 4 976 1140
women any A rs11722059 0.02734 1.29 (1.03,1.61) 4 570 682
men any G rs13115024 0.05038 0.61 (0.38, 1.00) 4 406 458
all paracentral A rs11722059 0.00406 1.50 (1.14, 1.98) 4 175 1140
women paracentral A rs11722059 0.00031 1.90 (1.34, 2.69) 4 106 682
men paracentral A rs4691842 0.01468 1.62 (1.10, 2.40) 4 69 458
Most significant single nucleotide polymorphisms (SNPs) stratified by gender and type of visual field (VF) loss. 51 SNPs were analyzed within the GUCY1A3/GUCY1B3
locus and 50 kb upstream and downstream of the region. A Bonferroni correction of 3.3610
24, correcting for analyzing 51 SNPs and 3 subgroups, was applied to define
statistical significance. The top SNP (rs11722059) reached significance in women with paracentral visual field (VF) loss (P value of 3.1610
24, bold and italicized). MA:
minor allele; OR: multivariable odds ratio associated with each minor allele dose, generated by multiple logistic regression analyses adjusting for age, gender, study site,
DNA source, DNA extraction method, and three eigenvectors; CI: confidence interval; Chr: chromosome; N: number.
doi:10.1371/journal.pone.0060156.t001
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2/2 mice. Vasoconstriction
likely results from baroreflex activation in response to an acute
drop in blood pressure or may be mediated by the renin-
angiotensin system, as previously described in other vascular beds
in response to circulatory shock [65]. Importantly, the decrease in
retinal arterial diameter upon NO administration was less
apparent in sGCa1
2/2 than in WT mice. The observation that
the retinal hemodynamic response to a decrease in blood pressure
is abnormal in sGCa1
2/2 mice, suggests that impaired NO-cGMP
signaling is associated with retinal vascular dysfunction, just as it is
with systemic vascular dysfunction. In summary, sGCa1-deficiency
may result in optic neuropathy via a variety of mechanisms, either
by increasing IOP and/or by impairing retinal blood flow. In
addition, we cannot exclude the possibility that impaired NO-sGC
signaling sensitizes RGCs to small increases in IOP that may not
injure WT RGCs [66]. Also, we recognize that additional work is
necessary to examine the impact of gender on the development of
POAG in sGCa1
2/2 mice, especially in light of observations
suggesting that gender may play an important role in the
pathogenesis of POAG [26].
Although several mechanically- and chemically-induced models
of ganglion cell death and glaucoma have been developed in mice
[67,68] to date, only a few spontaneously-occurring murine
models of glaucoma that do not involve ocular manipulation have
been described. As they age, DBA/2J mice develop a progressive
form of secondary angle closure glaucoma [48]. TG-MYOC
Y437H
mice that overexpress a mutant form of the human myocilin
(MYOC) gene mimics human juvenile open-angle glaucoma and is
considered a model of POAG [69]. However, mutations in
MYOC account for only a minority of POAG cases. Cyp1b1
2/2
mice develop angle dysgenesis that mimics the congenital version
of open-angle glaucoma but these mice do not develop elevated
IOP [49]. More recently, transiently elevated IOP [70], optic
nerve damage [71], and decreased AqH outflow [72] were
described in mice with a targeted mutation in the type I collagen
gene. Our data suggests that sGCa1
2/2 mice are an additional
model of POAG that may be useful to study mechanisms of IOP
regulation and the role of vascular dysfunction in the etiology of
POAG.
Linkage analysis and genome-wide association studies have
identified several genes associated with POAG, a disease with
significant heritability [73,74]. Our identification, in an explor-
atory genetic analysis aimed at investigating the relevance of our
mouse model in human POAG, of a variant (rs11722059) in the
GUCY1A3/GUCY1B3 locus significantly associated with a subpop-
ulation of POAG patients characterized by paracentral scotomas,
is a step towards understanding the contribution of sGC to the
etiology of this important subtype of POAG. Interestingly,
rs11722059 is in linkage disequilibrium (D’=0.86; r
2=0.67) with
another GUCY1A3/GUCY1B3 SNP (rs13139571) that was recently
associated with blood pressure in 200,000 individuals of European
decent from the International Consortium for blood pressure [75].
Overall, these results identify a role for sGCa1b1 in the POAG
phenotype characterized by vascular dysregulation and paracen-
tral visual field loss, and suggest a possible mechanistic link
between blood pressure and POAG. Together with the previously
reported association between vascular dysfunction and POAG
[8,55], and with the finding that sGCa1-deficiency is associated
with both systemic and retinal vascular dysfunction, the results of
our candidate gene association study raises the possibility that
retinal vascular dysfunction contributes to the development of
POAG associated with impaired NO-cGMP signaling.
While the focus of this study was to categorize a new murine
model of POAG and identify a well-characterized signaling
mechanism (NO-cGMP signaling) as centrally involved in the
etiology of POAG, rather than to formally report on a new genetic
association, we recognize that the human genetic association
described requires confirmation in a replication cohort. Because
recruitment ascertainment typically targets patients more likely to
have peripheral visual field defects, there are currently no other
available POAG cohorts of sufficient size with paracentral scotoma
information that could be used for replication. For example, only
26 of 2170 cases in the NEI Glaucoma Human Genetics
Collaboration presented with initial paracentral loss [76]. In spite
of this limitation, we believe the genetic association data provided
highlights the significance of sGC-signaling in the etiology of
POAG and will motivate investigators to identify cohorts to
replicate the GLAUGEN finding.
In humans, several mechanisms have been identified that can
impair NO-cGMP signaling, potentially contributing to the
development of POAG. For example, a candidate gene association
study in 527 incident cases and 1543 controls revealed interactions
between NOS3 gene variants, potentially affecting expression
and/or activity of NOS3 (and, ultimately, sGC enzyme activity),
and high tension POAG in females [26]. Alternatively, the
mechanism by which increased oxidative stress results in POAG
[77] may involve direct oxidation and inactivation of sGC [78].
NO- and heme-independent sGC activators, capable of activating
oxidized sGC, such as cinaciguat [79], are available and are being
tested in the clinic for a variety of cardiovascular diseases [80].
Other potential therapeutic targets include proteins that control
GMP levels and which are abundantly present in the eye
(including cGMP-catabolizing phosphodiesterases [81] and par-
ticulate guanylate cyclases [82]). Pharmacological modulation of
the activity of these proteins may increase outflow, attenuate
retinal arterial dysfunction, and prevent disease progression.
Conclusions
Our results demonstrate that impairing a well-characterized
signaling pathway (NO-cGMP signaling) results in optic neurop-
athy, possibly by modulating IOP and retinal vascular function.
Our data identify sGCa1
2/2 mice as a novel translational animal
model for POAG, providing a tool for investigators to study the
pathogenesis of POAG and to test new strategies for disease
prevention. Furthermore, we identified a genomic locus containing
the sGCa1 and sGCb1 genes that is associated with glaucoma with
paracentral visual field loss in women. Together, these findings
identify sGC as a potential therapeutic target to treat POAG and
may inform the clinical development of existing cGMP-elevating
therapeutic compounds for treating glaucomatous retinal injury.
Supporting Information
Figure S1 SD-OCT analysis of retinal nerve fiber layer
thickness in sGCa1
2/2 mice. A: Representative heat maps of
absolute total retinal thickness and RNFL thickness in 12 month-
old wild-type (WT) and soluble guanylate cyclase a1-deficient
(sGCa1
2/2) mice. No differences in total retinal thickness were
detected between sGCa1
2/2 and WT mice (fig. 2A). RNFL
thickness was thinner in sGCa1
2/2 mice than in WT mice, as
demonstrated by the darker blue colors in the sGCa1
2/2 RNFL
heat map (see also fig. 2A). Color scale varies between 1.53 (black)
and 247.93 (white) mm. See fig. 2A for quantitative data. B:
Validation of the automated segmentation analysis. The manually
determined RNFL thickness data recapitulated the automated
segmentation analysis and confirmed that the RNFL is thinner in
old in sGCa1
2/2 mice than in old WT mice. Left panel:
Representative en-face image of the retina acquired using SD-
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grid at which RNFL thickness was measured, and B-scans (right,
A-E) showing placement of the 24 calipers used to measure RNFL
thickness. Middle panel: mean RNFL thickness measured in all
24 pre-defined points in WT (upper number) and sGCa1
2/2 mice
(lower number). Right panel: mean RNFL thickness (as averages
of RNFL thickness measured manually in 24 points), assessed
using a 2-way repeated measures ANOVA, did not differ in 6-
week-old sGCa1
2/2 and age-matched WT mice (n=15 and 20,
respectively; P=0.29), but was thinner in 70-week-old sGCa1
2/2
mice than in age-matched WT mice (n=17 each; *P=1.4610
22).
(TIF)
Figure S2 Intraocular pressure (IOP) increases with age
in sGCa1
2/2 mice. A: IOP in young (1566-week-old) and old
(39614-week-old) wild-type (WT) and soluble guanylate cyclase
a1-deficient (sGCa1
2/2) mice. No statistically significant differ-
ence in IOP was detected between young sGCa1
2/2 and age-
matched WT mice (n=61 and 112, respectively; P=0.08). In
contrast, IOP was higher in old sGCa1
2/2 mice than in age-
matched WT mice (n=468 and 140, respectively). *P=2.9610
27
vs. 39614-week-old WT. B: IOP in a second independent cohort
of WT eyes (n=27) measured serially at 2 time points. IOP was
1562 and 1561 mmHg in 3060 and 6260-week-old WT mice,
respectively. P=0.93. C: IOP in a second independent cohort of
sGCa1
2/2 eyes (n=41) measured serially at 2 time points. IOP
increased from 1562t o1 9 62 mmHg in 2664 and 7365-week-
old sGCa1
2/2 mice, respectively. *P=4.8610
216.
(TIF)
Figure S3 Fluorescein angiography in WT and sGCa1
2/
2 mice. A: Serial images (A–G) of fluorescein angiography
between 1 and 3 seconds after I.V. injection of fluorescein. Retinal
arterioles (arrows in panel A) were identified based on earlier
filling with fluorescein than veins (arrows in panel E). B: Image of
fluorescein angiography. The width of the arterioles was de-
termined (boxes) at fixed distances from the optic nerve head
(inner dashed ring =150 mm; outer dashed ring =250 mm). C:
Quantitative analysis of the diameter of retinal arterioles in wild
type (WT, left panel) and soluble guanylate cyclase a1-deficient
mice (sGCa1
2/2, middle panel) before and after a challenge
with 0.8 mg/kg sodium nitroprusside. Baseline diameter of retinal
arterioles was similar in WT and sGCa1
2/2 mice (P=0.40).
Injection of 0.8 mg/kg sodium nitroprusside reduced the diameter
of retinal arterioles in both WT (*P=7.8610
212) and sGCa1
2/2
mice (*P=1.7610
26). The change in diameter induced by
injection of sodium nitroprusside was more pronounced in WT
than in sGCa1
2/2 mice (right panel,* P=9.0610
26). n=17 and
15 WT and sGCa1
2/2 arterioles, respectively; 3–4 arterioles/
mouse from 5 mice, each. See also fig. 6B for data analysis per
mouse.
(TIF)
Movie S1 Representative movies of SD-OCT analyses of the
iridocorneal angle in age matched 12-month old wild-type (WT,
movie S1) and soluble guanylate cyclase a1-deficient mice
(movie S2). To demonstrate the ability of SD-OCT to discrim-
inate between open and closed angles we imaged a closed angle in
a 12-month-old DBA/2J mouse with elevated IOP (movie S3).
Movies are representative examples of images observed in at least
five mice per group in two replicate experiments.
(MOV)
Movie S2 Representative movies of SD-OCT analyses of the
iridocorneal angle in age matched 12-month old wild-type (WT,
movie S1) and soluble guanylate cyclase a1-deficient mice
(movie S2). To demonstrate the ability of SD-OCT to discrim-
inate between open and closed angles we imaged a closed angle in
a 12-month-old DBA/2J mouse with elevated IOP (movie S3).
Movies are representative examples of images observed in at least
five mice per group in two replicate experiments.
(MOV)
Movie S3 Representative movies of SD-OCT analyses of the
iridocorneal angle in age matched 12-month old wild-type (WT,
movie S1) and soluble guanylate cyclase a1-deficient mice
(movie S2). To demonstrate the ability of SD-OCT to discrim-
inate between open and closed angles we imaged a closed angle in
a 12-month-old DBA/2J mouse with elevated IOP (movie S3).
Movies are representative examples of images observed in at least
five mice per group in two replicate experiments.
(MOV)
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